Autor según el artículo: Tufano A, Ageno W, Di Micco P, Niglio A, Rosa V, Ballaz A, Braester A, Rubio CM, Isern V, Imbalzano E, Monreal M, RIETE Investigators
Departamento: Medicina i Cirurgia
Autor/es de la URV: Porras Ledantes, Jose Antonio
Palabras clave: Venous thromboembolism Trends Therapy Splanchnic vein thrombosis Riete registry Recurrences Multicenter Management International registry History Cirrhosis Bleeding Antithrombotic treatment Anticoagulant therapy recurrences bleeding anticoagulant therapy
Resumen: © 2018 Elsevier Ltd Introduction: Current guidelines recommend the use of anticoagulant therapy in patients with symptomatic splanchnic vein thrombosis (SVT) and suggest no routine anticoagulation in those with incidental SVT. Methods: We used the RIETE (Registro Informatizado Enfermedad Trombo Embólica) registry to assess the rate and severity of symptomatic venous thromboembolism (VTE) recurrences and major bleeding events appearing during the course of anticoagulation in patients with symptomatic or incidental SVT. Results: In March 2017, 521 patients with SVT were recruited. Of them, 212 (41%) presented with symptomatic SVT and 309 had incidental SVT. Most (93%) patients received anticoagulant therapy (median, 147 days). During the course of anticoagulation, 20 patients developed symptomatic VTE recurrences (none died) and 26 had major bleeding (fatal bleeding, 5). On multivariable analysis, patients with incidental SVT had a non-significantly higher risk for symptomatic VTE recurrences (adjusted hazard ratio [HR]: 2.04; 95%CI: 0.71–5.88) and a similar risk for major bleeding (HR: 1.12; 95%CI: 0.47–2.63) than those with symptomatic SVT. Active cancer was associated with at increased risk for VTE recurrences (HR: 3.06; 95%CI: 1.14–8.17) and anaemia (HR: 4.11; 95%CI: 1.45–11.6) or abnormal prothrombin time (HR: 4.10; 95%CI: 1.68–10.1) were associated with at increased risk for major bleeding. Conclusions: The rates of recurrent SVT and major bleeding were similar between patients with incidental or symptomatic SVT. Because the severity of bleeding complications during anticoagulation may outweigh the severity of VTE recurrences in both groups, further studies should identify those SVT patients who benefit from anticoagulant therapy.
Áreas temáticas: Saúde coletiva Química Psicología Peripheral vascular disease Medicina iii Medicina ii Medicina i Interdisciplinar Hematology General medicine Farmacia Ensino Ciências biológicas iii Ciências biológicas ii Ciências biológicas i Biotecnología Biodiversidade Astronomia / física
Acceso a la licencia de uso: https://creativecommons.org/licenses/by/3.0/es/
ISSN: 00493848
Direcció de correo del autor: joseantonio.porras@urv.cat
Identificador del autor: 0000-0001-6418-1822
Fecha de alta del registro: 2024-09-07
Versión del articulo depositado: info:eu-repo/semantics/acceptedVersion
Enlace a la fuente original: https://www.thrombosisresearch.com/article/S0049-3848(18)30215-9/fulltext
URL Documento de licencia: https://repositori.urv.cat/ca/proteccio-de-dades/
Referencia al articulo segun fuente origial: Thrombosis Research. 164 69-74
Referencia de l'ítem segons les normes APA: Tufano A, Ageno W, Di Micco P, Niglio A, Rosa V, Ballaz A, Braester A, Rubio CM, Isern V, Imbalzano E, Monreal M, RIETE Investigators (2018). Outcomes during anticoagulation in patients with symptomatic vs. incidental splanchnic vein thrombosis. Thrombosis Research, 164(), 69-74. DOI: 10.1016/j.thromres.2018.02.143
DOI del artículo: 10.1016/j.thromres.2018.02.143
Entidad: Universitat Rovira i Virgili
Año de publicación de la revista: 2018
Tipo de publicación: Journal Publications